Clinical Trial Update: First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma [Phase 1]

View source ↗

Summary

First-time-in-human Phase 1 trial evaluating safety, tolerability, immunogenicity, PK, and PD of GSK3511294 given subcutaneously in adults with mild to moderate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• GSK3511294

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 1 | Status: COMPLETED | Results posted: 2021-03-01